Online inquiry

IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2779MR)

This product GTTS-WQ2779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL1 gene. The antibody can be applied in Allergic asthma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001282408.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 9173
UniProt ID Q01638
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2779MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ237MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ7333MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ8758MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ3569MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ476MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ15012MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ5697MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ5647MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP870
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW